Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Concurrent Chemoradiotherapy for Locally Advanced Resectable ESCC
NCT07622797Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Started Nov 2025; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07622797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622797.